These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27216057)

  • 1. Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
    Custodio JM; Fordyce M; Garner W; Vimal M; Ling KH; Kearney BP; Ramanathan S
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5135-40. PubMed ID: 27216057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
    Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
    Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
    EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
    Margot N; Ram R; Abram M; Haubrich R; Callebaut C
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
    Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
    Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
    Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
    Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
    [No Abstract]   [Full Text] [Related]  

  • 11. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
    Brooks KM; Castillo-Mancilla JR; Morrow M; MaWhinney S; Blum J; Wyles DL; Rowan SE; Ibrahim ME; Zheng JH; Johnson B; Gomez J; Choi YJ; Cendali F; Haas H; Roon L; Bushman LR; Anderson PL; Kiser JJ
    J Antimicrob Chemother; 2020 Nov; 75(11):3303-3310. PubMed ID: 32766700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tenofovir alafenamide fumarate - a new generation of tenofovir].
    Snopková S; Havlíčková K; Husa P
    Klin Mikrobiol Infekc Lek; 2016 Sep; 22(3):111-117. PubMed ID: 27907972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
    Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
    J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.
    Bevers LAH; Kamphuis AEM; van der Wekken-Pas LCW; Leisegang R; Burger DM; Colbers A
    Clin Pharmacokinet; 2024 May; 63(5):721-728. PubMed ID: 38573477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
    Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
    AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
    Huliciak M; Lhotska I; Kocova-Vlckova H; Halodova V; Dusek T; Cecka F; Staud F; Vokral I; Cerveny L
    Pharm Res; 2023 Sep; 40(9):2109-2120. PubMed ID: 37594591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.
    Callebaut C; Liu Y; Babusis D; Ray A; Miller M; Kitrinos K
    PLoS One; 2017; 12(2):e0169948. PubMed ID: 28182625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.
    Yamada H; Yonemura T; Nemoto T; Ninomiya N; Irie S
    Clin Pharmacol Drug Dev; 2019 May; 8(4):511-520. PubMed ID: 30325567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.